Literature DB >> 11193723

Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.

S Kubo1, K Hirohashi, H Tanaka, T Tsukamoto, T Shuto, T Ikebe, T Yamamoto, K Wakasa, S Nishiguchi, T Kuroki, H Kinoshita.   

Abstract

Although there have been many studies of the risk factors for recurrence after resection of hepatocellular carcinoma (HCC), the subjects were patients with various viral status in the previous studies, and hepatitis C viremia has not been evaluated. We investigated risk factors, including hepatic C viremia and histologic findings of noncancerous hepatic tissue, for recurrence after resection of hepatitis C virus (HCV)-related HCC. A total of 223 patients who underwent liver resection for HCV-related HCC were studied. HCV viremia, laboratory data, degree of HCC malignancy, histologic findings in noncancerous hepatic tissue, preoperative interferon therapy, and operative methods were evaluated for recurrence risk by univariate and multivariate analyses. Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin, and the proportion of patients with a high histologic activity score (mild to severe active hepatitis) were significantly higher in patients with HCV viremia than in those without viremia. Serum albumin was significantly lower in patients with HCV viremia. By univariate analysis, older age (> 65 years old), HCV viremia, elevated AST (> 40 IU/L) and ALT (> 45 IU/L), large tumors (> 40 mm), multiple HCCs, moderately or poorly differentiated HCC, portal invasion, mild to severe active hepatitis, and lack of preoperative interferon therapy were risk factors for recurrence. Multivariate analysis showed that older age, HCV viremia, high AST, multiple HCCs, and portal invasion were independent risk factors. For HCV-related HCCs, not only the degree of malignancy of the HCC but also HCV viremia and active hepatitis are risk factors for recurrence.

Entities:  

Mesh:

Year:  2000        PMID: 11193723     DOI: 10.1007/s002680010277

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  19 in total

1.  Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B.

Authors:  Shoji Kubo; Kazuhiro Hirohashi; Osamu Yamazaki; Mitsuharu Matsuyama; Hiromu Tanaka; Katsuhiko Horii; Taichi Shuto; Takatsugu Yamamoto; Shuichi Kawai; Kenichi Wakasa; Shuhei Nishiguchi; Hiroaki Kinoshita
Journal:  World J Surg       Date:  2002-02-19       Impact factor: 3.352

2.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

3.  Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  Behnoosh R Momin; Paulo S Pinheiro; Helena Carreira; Chunyu Li; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

Review 4.  Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus.

Authors:  Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takahiro Uenishi
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

5.  Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: retrospective study from HCV-endemic areas.

Authors:  Atsushi Sasaki; Yukio Iwashita; Kohei Shibata; Toshifumi Matsumoto; Masayuki Ohta; Seigo Kitano
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

6.  Surgical treatment for hepatocellular carcinoma detected after successful interferon therapy.

Authors:  Shoji Kubo; Hiromu Tanaka; Shigekazu Takemura; Satoshi Yamamoto; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Taichi Shuto; Kazuhiro Hirohashi
Journal:  Surg Today       Date:  2007-03-26       Impact factor: 2.549

7.  Risk factors for postoperative delirium after liver resection for hepatocellular carcinoma.

Authors:  Yasuko Yoshimura; Shoji Kubo; Kumiko Shirata; Kazuhiro Hirohashi; Hiromu Tanaka; Taichi Shuto; Shigekazu Takemura; Hiroaki Kinoshita
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

8.  Pulmonary resection for non-small cell lung cancer in patients with hepatocellular carcinoma.

Authors:  Takashi Iwata; Noritoshi Nishiyama; Koshi Nagano; Nobuhiro Izumi; Shinjiro Mizuguchi; Ryuhei Morita; Takuma Tsukioka; Shoji Hanada; Kiyotoshi Inoue; Shoji Kubo; Shigekazu Takemura; Shigefumi Suehiro
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

9.  Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Shoji Kubo; Shigekazu Takemura; Takahiro Uenishi; Takatsugu Yamamoto; Kazuki Ohba; Masao Ogawa; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Hiromu Tanaka
Journal:  World J Surg       Date:  2008-04       Impact factor: 3.352

10.  Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.

Authors:  Masaki Kaibori; Yoichi Matsui; Hidesuke Yanagida; Norio Yokoigawa; A-Hon Kwon; Yasuo Kamiyama
Journal:  World J Surg       Date:  2004-06-08       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.